8-K - AN2 Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

On March 19, 2026, the Board of AN2 Therapeutics, Inc. approved a stock option repricing of all outstanding Eligible Options under the 2017 and 2022 Equity Incentive Plans to $3.91 per share, including options held by named executive officers and non-employee directors. This provides retention incentives without stock dilution or additional cash costs.

Key Takeaways

1Option Repricing effective March 19, 2026, reducing exercise price to $3.91 per share for all Eligible Options prior to that date

2Applies to stock options held by named executive officers and non-employee Board members

3Eric Easom (President, CEO, Board chair): 742,649 Eligible Options, original prices $6.60-$17.28 per share

4Joshua Eizen (Chief Legal Officer, COO): 142,150 Eligible Options, original prices $14.29-$17.88 per share

5Lucy Day (CFO): 221,965 Eligible Options, original prices $6.60-$17.28 per share

6Premium End Date is earliest of September 19, 2027, change in control, or holder's death/disability; early exercise requires original price payment

Current Report Details

Event Type

Management Change

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 19

Management Change

$3.91$6.60$17.28$14.29

Executive & Director Changes

Eric Easom

President, Chief Executive Officer and Board chair

stock options repriced

Effective: 2026-03-19

Joshua Eizen

Chief Legal Officer and Chief Operating Officer

stock options repriced

Effective: 2026-03-19

Lucy Day

Chief Financial Officer

stock options repriced

Effective: 2026-03-19

Non-employee members of the Board

Directors

stock options repriced

Effective: 2026-03-19

Exhibits (1)

8-K